The pCR rate for the breast and axilla was 54% for the anthracycline/taxane backbone-plus-carboplatin group versus 41% for the anthracycline/taxane backbone-alone group (P= .0029).
Evidence (adding pembrolizumab to a chemotherapy regimen in patients with stage II or stage III TNBC): The randomized, double blind, phase IIIKEYNOTE-522trial (NCT03036488) evaluated the addition of immunotherapy to neoadjuvant chemotherapy for patients with stage II and stage III TNBC.[106][Level of evidence B1] Participants were randomly assigned in a 2:1 ratio to receive neoadjuvant chemotherapy (paclitaxel plus carboplatin, followed by doxorubicin plus cyclophosphamide) with either neoadjuvant and adjuvant pembrolizumab or neoadjuvant and adjuvant placebo.